A detailed history of Logos Global Management LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Logos Global Management LP holds 150,000 shares of JANX stock, worth $6.28 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
150,000
Holding current value
$6.28 Million
% of portfolio
0.53%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $1.19 Million - $7.46 Million
150,000 New
150,000 $5.65 Million
Q1 2022

May 16, 2022

SELL
$13.24 - $20.24 $2.45 Million - $3.75 Million
-185,196 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$15.44 - $27.32 $956,137 - $1.69 Million
-61,926 Reduced 25.06%
185,196 $3.65 Million
Q3 2021

Nov 15, 2021

SELL
$20.7 - $34.69 $6.21 Million - $10.4 Million
-300,000 Reduced 54.83%
247,122 $4.81 Million
Q2 2021

Aug 16, 2021

BUY
$18.58 - $25.37 $10.2 Million - $13.9 Million
547,122 New
547,122 $13.7 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $1.75B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Logos Global Management LP Portfolio

Follow Logos Global Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Logos Global Management LP with notifications on news.